ArticleAdvanced healthcare materials2026
MAP Crosslinker Chirality Regulates Macrophage Polarization Through MD-2 Engagement and Enables Tunable Immunomodulation Through Novel Peptide Design.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Microporous annealed particle (MAP) scaffolds are injectable hydrogel biomaterials that promote tissue regeneration by enabling rapid cell infiltration and presenting reparative cues. Previous work showed that substituting L- with D-chiral residues in matrix metalloproteinase (MMP)-degradable crosslinkers induces adaptive immune-mediated skin regeneration and balanced macrophage responses in vivo, but the underlying mechanisms remain unclear. Here, we identify myeloid differentiation factor 2 (MD-2)-associated TLR4 signaling as a key mechanistic contributor to macrophage polarization driven by crosslinker chirality in MAP scaffolds. Macrophages cultured in D-chiral MAP (DMAP) scaffolds exhibited reduced iNOS, CD86, and TNF-α expression and shifted from an M1-like state toward M0-like phenotypes compared to L-chiral MAP (LMAP) and 2D controls. Competitive inhibition with soluble D-chiral MMP crosslinker peptide (DMMP) partially restored M1 activation, implicating direct peptide-macrophage interactions. Docking and surface plasmon resonance (SPR) analyses revealed higher-affinity binding of DMMP to MD-2 relative to L-chiral peptides. Accordingly, DMAP altered TLR4/MD-2 trafficking and attenuated endocytosis-dependent signaling. Engineering a second D-peptide crosslinker with enhanced MD-2 affinity (DMMP2) reduced inflammatory markers and promoted regenerative macrophage polarization. Together, these results establish peptide chirality as a tunable design parameter for modulating TLR4/MD-2 signaling and engineering immunomodulatory MAP scaffolds.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.